Home › Funds › Samsara BioCapital, LLC › SRRK
Samsara BioCapital, LLC position in SRRK
SCHOLAR ROCK HLDG CORP · Health Care
Samsara BioCapital, LLC reported holding 6,897,652 shares of SRRK (SCHOLAR ROCK HLDG CORP) in its Q3 2026 13F filing — a position valued at US$333.3M, representing 31.69% of its reported portfolio and ranking #1 among its reported holdings. Samsara BioCapital, LLC has disclosed SRRK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Samsara BioCapital, LLC's SRRK position evolved
Samsara BioCapital, LLC first disclosed a stake in SRRK in Q3 2023 at 4,598,828 shares (US$32.7M). The position peaked in Q2 2026 at 6,897,652 shares, worth US$379.4M. Across 13 filings, Samsara BioCapital, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 6,897,652 shares valued at US$333.3M. Notable position changes include a 48% increase in Q4 2023 (shares fell 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.60M | $32.65M | New |
| Q4 2023 | 6.79M | $127.63M | Add |
| Q1 2024 | 6.79M | $120.57M | Hold |
| Q2 2024 | 6.79M | $56.55M | Hold |
| Q3 2024 | 6.79M | $54.38M | Hold |
| Q4 2024 | 5.61M | $242.59M | Reduce |
| Q1 2025 | 5.61M | $180.45M | Hold |
| Q2 2025 | 5.61M | $198.81M | Hold |
| Q3 2025 | 5.61M | $209.02M | Hold |
| Q4 2025 | 6.90M | $303.84M | Add |
| Q1 2026 | 6.90M | $339.09M | Hold |
| Q2 2026 | 6.90M | $379.37M | Hold |
| Q3 2026 | 6.90M | $333.29M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SRRK and 13F data
SRRK (SCHOLAR ROCK HLDG CORP) is a Health Care company. 46 other funds we track also report a position in SRRK — the largest reported positions include Siren, L.L.C. (US$453.0M), Orbis Allan Gray Ltd (US$293.6M), Redmile Group, LLC (US$146.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SRRK
- Siren, L.L.C. 9.38M sh · $453.00M · Q3 2026
- Orbis Allan Gray Ltd 6.08M sh · $293.56M · Q3 2026
- Redmile Group, LLC 3.03M sh · $146.60M · Q3 2026
- Bellevue Group AG 2.79M sh · $134.66M · Q3 2026
- ARCH Venture Management, LLC 2.35M sh · $113.34M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.32M sh · $112.13M · Q3 2026
- Hood River Capital Management LLC 2.25M sh · $108.81M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 2.08M sh · $100.40M · Q3 2026
- Integral Health Asset Management, LLC 1.25M sh · $60.64M · Q3 2026
- Casdin Capital 850.00K sh · $41.07M · Q3 2026
More on Samsara BioCapital, LLC
FAQ
How long has Samsara BioCapital, LLC held SRRK?
Samsara BioCapital, LLC has disclosed SRRK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Samsara BioCapital, LLC's current position in SRRK?
As of Q3 2026, Samsara BioCapital, LLC holds 6.90M shares of SRRK (SCHOLAR ROCK HLDG CORP), valued at $333.29M, representing 31.69% of its reported portfolio and ranking #1.
Has Samsara BioCapital, LLC been buying or selling SRRK?
In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC held unchanged its position in SRRK. The position peaked in Q2 2026 at 6.90M shares.
Which other funds hold SRRK?
Other major institutional holders of SRRK include Siren, L.L.C., Orbis Allan Gray Ltd, Redmile Group, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.